Mabion S.A. Net Assets
Mabion S.A. net assets. Based on the latest financial reports, Mabion S.A. (MAB) has net assets worth zł24.15 Million PLN (≈ $6.65 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł102.20 Million ≈ $28.13 Million USD) and total liabilities (zł78.05 Million ≈ $21.48 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore MAB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł24.15 Million |
| % of Total Assets | 23.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | 3.82% |
| 10-Year Change | 1384.37% |
| Growth Volatility | 2530.25 |
Net Assets of Mabion S.A. (2009–2025)
Net assets of Mabion S.A. from 2009 to 2025. This chart illustrates how Mabion S.A.'s net assets have evolved over time, based on quarterly financial data. See Mabion S.A. balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Mabion S.A. (2009–2025)
The table below shows the annual net assets of Mabion S.A. from 2009 to 2025. For live market cap and overall valuation, see MAB stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | zł55.35 Million ≈ $15.23 Million |
-50.33% |
| 2024-12-31 | zł111.44 Million ≈ $30.67 Million |
-5.38% |
| 2023-12-31 | zł117.78 Million ≈ $32.41 Million |
+53.94% |
| 2022-12-31 | zł76.51 Million ≈ $21.06 Million |
+43.51% |
| 2021-12-31 | zł53.31 Million ≈ $14.67 Million |
+168.89% |
| 2020-12-31 | zł-77.39 Million ≈ $-21.30 Million |
-258.61% |
| 2019-12-31 | zł-21.58 Million ≈ $-5.94 Million |
-151.21% |
| 2018-12-31 | zł42.14 Million ≈ $11.60 Million |
+177.81% |
| 2017-12-31 | zł-54.16 Million ≈ $-14.91 Million |
-1552.35% |
| 2016-12-31 | zł3.73 Million ≈ $1.03 Million |
-97.08% |
| 2015-12-31 | zł127.64 Million ≈ $35.13 Million |
-87.21% |
| 2014-12-31 | zł997.84 Million ≈ $274.62 Million |
+91.69% |
| 2013-12-31 | zł520.55 Million ≈ $143.26 Million |
-71.47% |
| 2012-12-31 | zł1.82 Billion ≈ $502.09 Million |
+8858.29% |
| 2011-12-31 | zł20.37 Million ≈ $5.60 Million |
-6.23% |
| 2010-12-31 | zł21.72 Million ≈ $5.98 Million |
+29137.19% |
| 2009-12-31 | zł-74.80K ≈ $-20.59K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mabion S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21284820202.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Mabion S.A. Net Assets Breakdown (December 2025)
Mabion S.A. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł1.62 Million | 3.31% |
| Other Comprehensive Income | zł23.19 Million | 47.50% |
| Other Components | zł237.44 Million | 486.28% |
| Total Equity | zł48.83 Million | 100.00% |
Mabion S.A. Competitors by Market Cap
The table below lists competitors of Mabion S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Veranda Learning Solutions Limited
NSE:VERANDA
|
$34.70 Million |
|
Namuga Co. Ltd
KQ:190510
|
$34.71 Million |
|
Optomed PLC
HE:OPTOMED
|
$34.73 Million |
|
Abico FS Co Ltd
TWO:8071
|
$34.74 Million |
|
DKLS Industries Bhd
KLSE:7528
|
$34.68 Million |
|
Co2 Capsol AS
OL:CAPSL
|
$34.67 Million |
|
ContextVision AB
OL:CONTX
|
$34.66 Million |
|
Arribatec Solutions ASA
OL:ARR
|
$34.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mabion S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 111,442,000 to 48,828,000, a change of -62,614,000 (-56.2%).
- Net loss of 62,614,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-62.61 Million | -128.23% |
| Total Change | zł- | -56.19% |
Book Value vs Market Value Analysis
This analysis compares Mabion S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.58x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | zł-0.01 | zł7.80 | x |
| 2010-12-31 | zł3.15 | zł7.80 | x |
| 2011-12-31 | zł4.17 | zł7.80 | x |
| 2012-12-31 | zł342.28 | zł7.80 | x |
| 2013-12-31 | zł65.64 | zł7.80 | x |
| 2014-12-31 | zł99.20 | zł7.80 | x |
| 2015-12-31 | zł11.73 | zł7.80 | x |
| 2016-12-31 | zł0.32 | zł7.80 | x |
| 2017-12-31 | zł-4.59 | zł7.80 | x |
| 2018-12-31 | zł3.22 | zł7.80 | x |
| 2019-12-31 | zł-1.57 | zł7.80 | x |
| 2020-12-31 | zł-5.64 | zł7.80 | x |
| 2021-12-31 | zł3.43 | zł7.80 | x |
| 2022-12-31 | zł4.73 | zł7.80 | x |
| 2023-12-31 | zł7.29 | zł7.80 | x |
| 2024-12-31 | zł6.90 | zł7.80 | x |
| 2025-12-31 | zł3.02 | zł7.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mabion S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -128.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -397.37%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 2.26x
- Recent ROE (-128.23%) is below the historical average (-102.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | zł-321.27K |
| 2010 | 2.17% | 30.86% | 0.07x | 1.08x | zł-1.70 Million |
| 2011 | -6.65% | -137.41% | 0.04x | 1.32x | zł-3.39 Million |
| 2012 | -0.12% | -239.77% | 0.00x | 2.17x | zł-184.56 Million |
| 2013 | -0.75% | -67089.66% | 0.00x | 1.45x | zł-55.95 Million |
| 2014 | -0.45% | -537.69% | 0.00x | 1.48x | zł-104.25 Million |
| 2015 | -3.60% | -168.20% | 0.01x | 1.52x | zł-17.36 Million |
| 2016 | -1497.08% | 0.00% | 0.00x | 24.47x | zł-56.20 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | zł-52.47 Million |
| 2018 | -163.44% | 0.00% | 0.00x | 3.43x | zł-73.08 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | zł-62.55 Million |
| 2020 | 0.00% | -3596.73% | 0.02x | 0.00x | zł-49.45 Million |
| 2021 | 3.57% | 3.35% | 0.31x | 3.46x | zł-3.43 Million |
| 2022 | 30.31% | 14.14% | 0.88x | 2.43x | zł15.54 Million |
| 2023 | 35.04% | 27.21% | 0.73x | 1.77x | zł29.49 Million |
| 2024 | -5.68% | -9.18% | 0.43x | 1.43x | zł-17.48 Million |
| 2025 | -128.23% | -397.37% | 0.14x | 2.26x | zł-67.50 Million |
Industry Comparison
This section compares Mabion S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $219,391,249
- Average return on equity (ROE) among peers: -60.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mabion S.A. (MAB) | zł24.15 Million | 0.00% | 3.23x | $34.70 Million |
| Bioton S.A. (BIO) | $1.39 Billion | -0.47% | 0.37x | $82.95 Million |
| Captor Therapeutics S.A. (CTX) | $3.43 Million | -128.88% | 4.26x | $77.02 Million |
| Molecure S.A. (MOC) | $126.45 Million | -10.71% | 0.09x | $30.05 Million |
| Nanogroup SA (NNG) | $14.17 Million | -14.21% | 0.60x | $20.27 Million |
| Pharmena S.A. (PHR) | $12.42 Million | -10.16% | 0.09x | $8.49 Million |
| PolTREG S.A. (PTG) | $69.23 Million | -27.02% | 0.48x | $26.31 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $311.70K | -138.89% | 2.05x | $4.37 Million |
| Ryvu Therapeutics SA (RVU) | $343.39 Million | -24.40% | 0.38x | $105.37 Million |
| Synthaverse S.A. (SVE) | $20.00 Million | -186.17% | 7.31x | $53.91 Million |
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartere… Read more